Cargando…

The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma

Metastatic melanoma is the deadliest form of skin cancer whose incidence has been rising dramatically over the last few decades. Nowadays, the most successful approach in treating advanced melanoma is immunotherapy which encompasses the use of immune checkpoint blockers able to unleash the immune sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fattore, Luigi, Ruggiero, Ciro Francesco, Liguoro, Domenico, Castaldo, Vittorio, Catizone, Angiolina, Ciliberto, Gennaro, Mancini, Rita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013996/ https://www.ncbi.nlm.nih.gov/pubmed/33816298 http://dx.doi.org/10.3389/fonc.2021.645069

Ejemplares similares

Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma
por: Fattore, Luigi, et al.
Publicado: (2019)

Upregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin
por: Castaldo, Vittorio, et al.
Publicado: (2023)

In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2020)

Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance
por: Fattore, Luigi, et al.
Publicado: (2022)

ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin
por: Ruggiero, Ciro Francesco, et al.
Publicado: (2019)

Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma
por: Fattore, Luigi, et al.
Publicado: (2020)

MicroRNAs in melanoma development and resistance to target therapy
por: Fattore, Luigi, et al.
Publicado: (2017)

Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma
por: Ruggiero, Ciro Francesco, et al.
Publicado: (2022)

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma
por: Fattore, Luigi, et al.
Publicado: (2018)

Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization
por: Fattore, Luigi, et al.
Publicado: (2020)

Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach
por: Ricciardi, Elena, et al.
Publicado: (2023)

The promise of anti-ErbB3 monoclonals as new cancer therapeutics
por: Aurisicchio, Luigi, et al.
Publicado: (2012)

Is Tissue Still the Issue? The Promise of Liquid Biopsy in Uveal Melanoma
por: de Bruyn, Daniël P., et al.
Publicado: (2022)

Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition
por: Fattore, Luigi, et al.
Publicado: (2014)

Emerging Cancer Vaccines: The Promise of Genetic Vectors
por: Aurisicchio, Luigi, et al.
Publicado: (2011)

ERK Signaling Pathway Is Constitutively Active in NT2D1 Non-Seminoma Cells and Its Inhibition Impairs Basal and HGF-Activated Cell Proliferation
por: Gesualdi, Luisa, et al.
Publicado: (2023)

Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
por: Fattore, Luigi, et al.
Publicado: (2013)

Liquid biopsy for lung cancer immunotherapy
por: Cai, Liang-Liang, et al.
Publicado: (2019)

Extracellular Vesicles and the Promise of Continuous Liquid Biopsies
por: Armstrong, Don, et al.
Publicado: (2018)

Delivering on the promise of early detection with liquid biopsies
por: Crosby, David
Publicado: (2022)

microRNA-378a-5p iS a novel positive regulator of melanoma progression
por: Tupone, Maria Grazia, et al.
Publicado: (2020)

Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma
por: Fattore, Luigi, et al.
Publicado: (2015)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
por: Piérard, Gérald E., et al.
Publicado: (2012)

Role of liquid biopsy for thoracic cancers immunotherapy
por: Di Liello, Raimondo, et al.
Publicado: (2020)

The emerging role of cancer cell plasticity and cell-cycle quiescence in immune escape
por: Bruschini, Sara, et al.
Publicado: (2020)

ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors
por: Fattore, Luigi, et al.
Publicado: (2015)

Exosomal lncRNAs: the newest promising liquid biopsy
por: Tellez-Gabriel, Marta, et al.
Publicado: (2019)

Cancer metabolites: promising biomarkers for cancer liquid biopsy
por: Wang, Wenxiang, et al.
Publicado: (2023)

Liquid Biopsy Is a Promising Tool for Genetic Testing in Idiopathic Pulmonary Fibrosis
por: Pallante, Pierlorenzo, et al.
Publicado: (2021)

The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy
por: Banna, Giuseppe Luigi, et al.
Publicado: (2019)

Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response
por: Valenti, Fabio, et al.
Publicado: (2021)

Drug repurposing against COVID-19: focus on anticancer agents
por: Ciliberto, Gennaro, et al.
Publicado: (2020)

Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy
por: Nagayama, Satoshi, et al.
Publicado: (2021)

Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy
por: Maravelia, Panagiota, et al.
Publicado: (2021)

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy
por: Magbanua, Mark Jesus M., et al.
Publicado: (2022)

Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
por: Ao, Huang, et al.
Publicado: (2021)

Exosomal circRNAs as promising liquid biopsy biomarkers for glioma
por: Wu, Xiaoke, et al.
Publicado: (2023)

c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells
por: Leonetti, Erica, et al.
Publicado: (2019)

Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk
por: Velez, Gabriel, et al.
Publicado: (2021)

BAP31, a promising target for the immunotherapy of malignant melanomas
por: Yu, Shaojuan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_03ftq8epvdd439eck7hpb2cbvk